Skip to main content

Lipocine Inc.

LPCN
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001535955

In the last 90 days, Lipocine Inc. insiders filed 3 open-market purchases and 0 sales; 37 institutions reported holding it in 13F filings for Q2 2026, worth $7.63M in total; no superinvestor holds it.

Key figures

Market capClose on Nov 13, 2026
$18.9M
Insider buysLast 90 days, $161.7K in total
3
Insider sellsOpen market, last 90 days
0
13F holdersQ2 2026, −10 vs. previous quarter
37
13F valueReported value at the end of Q2 2026
$7.63M
Superinvestors holdingAt the end of Q2 2026
0

Price chart

From SEC filings, in USD.

Revenue, FY2025
$1.98M
−82.3% year over year
Net income, FY2025
-$9.63M
−115,371.9% year over year
Free cash flow, FY2025
–
No comparable prior period
Revenue, Q3 FY2026
$2.29M
+1,898.8% year over year

Revenue flow, FY2025

Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.

Net loss for FY2025: $9.63M (487.1% of revenue).

Short interest

See short data

From FINRA, settlement date Oct 30, 2026.

Short interest
325.4K
Shares sold short
Change
−26.0K
−7.4% vs. previous
Days to cover
1.50
At average daily volume

Superinvestors holding LPCN, Q2 2026

Go to the superinvestors tab

No superinvestor reported holding LPCN at the end of Q2 2026.

Latest insider trades

See all insider trades

Open-market purchases and sales by Lipocine Inc. insiders from Form 4, newest first.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Nov 13, 2026 (view filing)3:23 PM ETNov 12-131 dayPatel Mahesh V.Chief Executive OfficerPPurchase+50.0K$1.59+$79.5K+31.0%211.5K after2 lots
Oct 1, 2026 (view filing)8:28 PM ETSep 29-302 daysHiguchi John W.DirectorPPurchase+25.0K$2.20+$55.0K+11.6%241.4K after2 lots
Sep 30, 2026 (view filing)8:38 PM ETSep 282 daysHiguchi John W.DirectorPPurchase+12.6K$2.16+$27.1K+6.2%216.4K after
Apr 7, 2026 (view filing)Apr 7Same dayHiguchi John W.DirectorPPurchase+40.0K$2.03+$81.2K+24.4%203.8K after
Apr 6, 2026 (view filing)Apr 6Same dayHiguchi John W.DirectorPPurchase+123.0K$2.05+$252.2K+301.5%163.8K after
Apr 6, 2026 (view filing)Apr 6Same dayPatel Mahesh V.Chief Executive OfficerPPurchase+25.0K$2.03+$50.8K+18.4%160.7K after
Apr 2, 2026 (view filing)Apr 2Same dayPatel Mahesh V.Chief Executive OfficerPPurchase+25.0K$2.02+$50.5K+22.6%135.7K after
May 25, 2023 (view filing)May 25Same dayPatel Mahesh V.CEO and PresidentPPurchase+8.71K$5.03+$43.8K+8.8%107.4K after
Mar 24, 2023 (view filing)5:28 PM ETMar 24Same dayPatel Mahesh V.CEO and PresidentPPurchase+150.0K$0.32+$48.0K+9.8%1.68M after
Mar 20, 2023 (view filing)6:51 PM ETMar 20Same dayOno Richard DanaDirectorPPurchase+4.00K$0.34+$1.36K+39.5%14.1K after

Top 10 13F holders, Q2 2026

See all 37 holders

The largest institutional positions in Lipocine Inc. at the end of Q2 2026; share changes are against Q1 2026.

Institutions holding LPCN in Q2 2026
InstitutionSharesValue% of portfolioChange in sharesAction
Squadron Capital Management LLC810,000$2.07M0.71%+360,000+80.0%Added
Ikarian Capital, LLC508,556$1.30M0.21%00.0%Unchanged
Eversept Partners, LP294,989$755.2K0.04%00.0%Unchanged
Vanguard Capital Management LLC230,823$590.9K0.00%+30,155+15.0%Added
Acadian Asset Management LLC170,417$435.0K0.00%+170,417New
Boothbay Fund Management, LLC140,487$359.6K0.01%00.0%Unchanged
Jane Street Group, LLC95,227$243.8K0.00%+75,200+375.5%Added
BlackRock, Inc.89,272$228.5K0.00%00.0%Unchanged
Two Sigma Investments, LP84,887$217.3K0.00%+51,137+151.5%Added
Citadel Advisors LLC81,221$207.9K0.00%+52,133+179.2%Added

Holders of 5% or more of LPCN

See all 2 holders and filings

Holders whose latest Schedule 13D or 13G filing reports 5% or more of Lipocine Inc..

Largest holders of LPCN from 13D and 13G filings
HolderLatest formStakeChangeFirst filedLatest filingFiling
Squadron Capital Management LLC13G/A9.80%810.0K shares+3.60 ppfrom 6.20%Dec 23, 20254 filingsAug 14, 2026SEC
Ikarian Capital, LLC13G6.30%508.6K sharesNewMay 15, 20261 filingMay 15, 2026SEC